Current status of robotic distal pancreatectomy: A systematic review

Roberto Cirocchi, Stefano Partelli, Andrea Coratti, Jacopo Desiderio, Amilcare Parisi, Massimo Falconi

Research output: Contribution to journalArticle

Abstract

Objective: The aim of this systematic review is to determine the potential advantages of robotic distal pancreatectomy (RDP). Study selection: Both randomized and non-randomized studies. Data extraction: Two investigators independently selected studies for inclusion by article abstraction and full text reviewing. Data synthesis: Five non-RCTs were included in the review. The feasibility of RDP (95.4%) and spleen-preserving rate is between 50% and 100%. Mean OT varied between 298 min and 398 min with only completely robotic procedures, whereas mean OT was 293 in "laparoscopic/robotic" technique. Postoperative length of hospital stay ranged from 7 days to 13.7 days. The 30-day postoperative overall morbidity resulted between 0 and 18% of patients. Conclusions: RDP is an emergent technology for which there are not yet sufficient data to draw definitive conclusions with respect to conventional or laparoscopic surgery. The mean duration of RDP is longer with Da Vinci robot, but hospital stay is shorter even if it is influenced by hospital protocols. We cannot make any conclusions comparing the outcomes to laparoscopic or open procedures here, since none of these studies are randomized, and we all know that most of these surgeons selected the easier cases for robotic procedures. For these reasons randomized controlled trials are recommended to better evaluate RDP cost-effectiveness.

Original languageEnglish
Pages (from-to)201-207
Number of pages7
JournalSurgical Oncology
Volume22
Issue number3
DOIs
Publication statusPublished - Sep 2013

Fingerprint

Pancreatectomy
Robotics
Length of Stay
Laparoscopy
Cost-Benefit Analysis
Spleen
Randomized Controlled Trials
Research Personnel
Technology
Morbidity

Keywords

  • Distal pandreatectomy
  • Robotic
  • Systematic review

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Current status of robotic distal pancreatectomy : A systematic review. / Cirocchi, Roberto; Partelli, Stefano; Coratti, Andrea; Desiderio, Jacopo; Parisi, Amilcare; Falconi, Massimo.

In: Surgical Oncology, Vol. 22, No. 3, 09.2013, p. 201-207.

Research output: Contribution to journalArticle

Cirocchi, R, Partelli, S, Coratti, A, Desiderio, J, Parisi, A & Falconi, M 2013, 'Current status of robotic distal pancreatectomy: A systematic review', Surgical Oncology, vol. 22, no. 3, pp. 201-207. https://doi.org/10.1016/j.suronc.2013.07.002
Cirocchi, Roberto ; Partelli, Stefano ; Coratti, Andrea ; Desiderio, Jacopo ; Parisi, Amilcare ; Falconi, Massimo. / Current status of robotic distal pancreatectomy : A systematic review. In: Surgical Oncology. 2013 ; Vol. 22, No. 3. pp. 201-207.
@article{1b0687cac9ae47ffb786188a87d3926f,
title = "Current status of robotic distal pancreatectomy: A systematic review",
abstract = "Objective: The aim of this systematic review is to determine the potential advantages of robotic distal pancreatectomy (RDP). Study selection: Both randomized and non-randomized studies. Data extraction: Two investigators independently selected studies for inclusion by article abstraction and full text reviewing. Data synthesis: Five non-RCTs were included in the review. The feasibility of RDP (95.4{\%}) and spleen-preserving rate is between 50{\%} and 100{\%}. Mean OT varied between 298 min and 398 min with only completely robotic procedures, whereas mean OT was 293 in {"}laparoscopic/robotic{"} technique. Postoperative length of hospital stay ranged from 7 days to 13.7 days. The 30-day postoperative overall morbidity resulted between 0 and 18{\%} of patients. Conclusions: RDP is an emergent technology for which there are not yet sufficient data to draw definitive conclusions with respect to conventional or laparoscopic surgery. The mean duration of RDP is longer with Da Vinci robot, but hospital stay is shorter even if it is influenced by hospital protocols. We cannot make any conclusions comparing the outcomes to laparoscopic or open procedures here, since none of these studies are randomized, and we all know that most of these surgeons selected the easier cases for robotic procedures. For these reasons randomized controlled trials are recommended to better evaluate RDP cost-effectiveness.",
keywords = "Distal pandreatectomy, Robotic, Systematic review",
author = "Roberto Cirocchi and Stefano Partelli and Andrea Coratti and Jacopo Desiderio and Amilcare Parisi and Massimo Falconi",
year = "2013",
month = "9",
doi = "10.1016/j.suronc.2013.07.002",
language = "English",
volume = "22",
pages = "201--207",
journal = "Surgical Oncology",
issn = "0960-7404",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Current status of robotic distal pancreatectomy

T2 - A systematic review

AU - Cirocchi, Roberto

AU - Partelli, Stefano

AU - Coratti, Andrea

AU - Desiderio, Jacopo

AU - Parisi, Amilcare

AU - Falconi, Massimo

PY - 2013/9

Y1 - 2013/9

N2 - Objective: The aim of this systematic review is to determine the potential advantages of robotic distal pancreatectomy (RDP). Study selection: Both randomized and non-randomized studies. Data extraction: Two investigators independently selected studies for inclusion by article abstraction and full text reviewing. Data synthesis: Five non-RCTs were included in the review. The feasibility of RDP (95.4%) and spleen-preserving rate is between 50% and 100%. Mean OT varied between 298 min and 398 min with only completely robotic procedures, whereas mean OT was 293 in "laparoscopic/robotic" technique. Postoperative length of hospital stay ranged from 7 days to 13.7 days. The 30-day postoperative overall morbidity resulted between 0 and 18% of patients. Conclusions: RDP is an emergent technology for which there are not yet sufficient data to draw definitive conclusions with respect to conventional or laparoscopic surgery. The mean duration of RDP is longer with Da Vinci robot, but hospital stay is shorter even if it is influenced by hospital protocols. We cannot make any conclusions comparing the outcomes to laparoscopic or open procedures here, since none of these studies are randomized, and we all know that most of these surgeons selected the easier cases for robotic procedures. For these reasons randomized controlled trials are recommended to better evaluate RDP cost-effectiveness.

AB - Objective: The aim of this systematic review is to determine the potential advantages of robotic distal pancreatectomy (RDP). Study selection: Both randomized and non-randomized studies. Data extraction: Two investigators independently selected studies for inclusion by article abstraction and full text reviewing. Data synthesis: Five non-RCTs were included in the review. The feasibility of RDP (95.4%) and spleen-preserving rate is between 50% and 100%. Mean OT varied between 298 min and 398 min with only completely robotic procedures, whereas mean OT was 293 in "laparoscopic/robotic" technique. Postoperative length of hospital stay ranged from 7 days to 13.7 days. The 30-day postoperative overall morbidity resulted between 0 and 18% of patients. Conclusions: RDP is an emergent technology for which there are not yet sufficient data to draw definitive conclusions with respect to conventional or laparoscopic surgery. The mean duration of RDP is longer with Da Vinci robot, but hospital stay is shorter even if it is influenced by hospital protocols. We cannot make any conclusions comparing the outcomes to laparoscopic or open procedures here, since none of these studies are randomized, and we all know that most of these surgeons selected the easier cases for robotic procedures. For these reasons randomized controlled trials are recommended to better evaluate RDP cost-effectiveness.

KW - Distal pandreatectomy

KW - Robotic

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=84883828624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883828624&partnerID=8YFLogxK

U2 - 10.1016/j.suronc.2013.07.002

DO - 10.1016/j.suronc.2013.07.002

M3 - Article

C2 - 23910929

AN - SCOPUS:84883828624

VL - 22

SP - 201

EP - 207

JO - Surgical Oncology

JF - Surgical Oncology

SN - 0960-7404

IS - 3

ER -